(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 September 2025 (25.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/199273 A1

(51) International Patent Classification:
C07D 487/10 (2006.01) *A61P 31/20* (2006.01)
A61K 31/01 (2006.01) *A61P 35/00* (2006.01)
A61K 31/506 (2006.01) *C07D 498/10* (2006.01)
A61K 31/5377 (2006.01)

(21) International Application Number:
PCT/US2025/020632

(22) International Filing Date:
20 March 2025 (20.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,984 22 March 2024 (22.03.2024) US
63/670,574 12 July 2024 (12.07.2024) US

(71) Applicant: **ALIGOS THERAPEUTICS, INC.** [US/US]; 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventor: **WU, Tongfei**; c/o Aligos Therapeutics, Inc., 1 Corporate Drive, 2nd Floor, South San Francisco, California 94080 (US).

(74) Agent: **MILLER, Kimberly J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, Fourteenth Floor, Irvine, California 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: METHODS AND COMPOSITIONS FOR TARGETING PD-L1

Figure 1B



ORTEP structure

(57) Abstract: The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-L1 or the PD-1/PD-L1 interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound as described herein, or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound as described herein, or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including, but not limited to, liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

WO 2025/199273 A1

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*